Vildaray M contains Vildagliptin. Vildaray M uses:
Vildaray M is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.
| Brand Name: | Vildaray M |
| Generic: | Vildagliptin |
| Weight: | 50.0 Mg |
| Type: | Tablet |
| Therapeutic Class: | Dipeptidyl Peptidase-4 (DPP-4) inhibitor |
| Manufacturer: | LLOYD HEALTHCARE PVT LTD |
| Price: | 101.87 |
| Last Updated: | 2020-11-21 18:15:00 |
Vildaray M contains Vildagliptin 50.0 Mg. Vildaray M doses
The recommended dose of Vildaray M is-
Vildaray M may be taken with or without a meal. No dosage adjustment is required in the elderly, or in patients with mild renal impairment.
The majority of adverse reactions were mild and transient, not requiring treatment discontinuations. Rare case of hepatic dysfunction is seen. Clinical trials of up to and more than 2 years’ duration did not show any additional safety signals or unforeseen risks when use this drug.
Vildaray M is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which is believed to exert its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones. Incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day, and levels are increased in response to a meal. These hormones are rapidly inactivated by the enzyme, DPP-4. The incretins are part of an endogenous system involved in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from pancreatic beta cells by intracellular signaling pathways involving cyclic AMP. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, leading to reduced hepatic glucose production. By increasing and prolonging active incretin levels, Vildaray M increases insulin release and decreases glucagon levels in the circulation in a glucose-dependent manner.
Caution should be exercised in patients aged 75 years and older due to limited clinical experience. It is recommended that Liver Function Tests (LFTs) are monitored prior to initiation of Vildaray M, at three monthly intervals in the first year and periodically thereafter. If transaminase levels are increased, patients should be monitored with a second liver function evaluation to confirm the finding and be followed thereafter with frequent liver function tests until the abnormality (ies) return(s) to normal. If AST or ALT persist at 3 x ULN, Vildaray M treatment should be stopped. Patients who develop jaundice or other signs of liver dysfunction should discontinue Vildaray M. Following withdrawal of treatment with Vildaray M and LFT normalization, treatment with Vildaray M should not be reinitiated. Due to limited clinical experience, use with caution in patients with congestive heart failure of New York Heart Association (NYHA) functional class I–II, and do not use in patients with NYHA functional class III-IV. Vildaray M is not recommended in patients with moderate to severe renal impairment.
In pharmacokinetic studies, no interactions were seen with pioglitazone, metformin, glibenclamide, digoxin, warfarin, amlodipine, ramipril, valsartan or simvastatin. As with other oral antidiabetic medicinal products the glucose-lowering effect of Vildaray M may be reduced by certain active substances, including thiazides, corticosteroids, thyroid products and sympathomimetics.
Pregnancy: There are no adequate data on the use of Vildaray M in pregnant women; hence the potential risk for human is unknown.Lactation: It is not known whether Vildaray M is excreted in human milk. Due to lack of human data, Vildaray M should not be used during lactation.
Vildaray M is contraindicated in patients with:
Paediatric use: Vildaray M is not recommended in patients 18 years of age
Store in a cool and dry place. Protect from light and moisture. Keep out of the reach of the children.
Vildaray M Tablet price in India 101.87